na hcr omers fund gp llc  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors na hcr omers fund gp llc check out list of companies and businesses related to na hcr omers fund gp llc find out na hcr omers fund gp llc address and contact details view other people related to na hcr omers fund gp llc  coworkers colleagues companions etc address  atlantic street suite  stamford  ct companies related to na hcr omers fund gp llc cikcompany namepositioncompany addresshcr hop fund lp atlantic street suite  stamford  na hcr omers fund gp llc on the web persons related to na hcr omers fund gp llc  hcr hop fund lpnamepositioncityna hcr hop fund gp llcstamfordna hcr omers fund gp llcstamford bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version hcr hop fund lp  list of ceos founders and company directors directorpedianet  list of ceos founders board members and company directors hcr hop fund lp list of persons related to the company hcr hop fund lp find out list of ceos founders board members and company directors of hcr hop fund lp cik number irs number company address  atlantic street suite  stamford phone number former name hcr omers fund lp date of change  people related to hcr hop fund lp namepositionstreetcitycountryna hcr hop fund gp llc atlantic street suite stamfordctna hcr omers fund gp llc atlantic street suite stamfordct hcr hop fund lp on the web related companieshcr stafford fund lp hcr value fund lp hcrp overflow fund lpseries b hcr value fund lp  who is raising money  sec filings of fundraisings and investments in hedge funds startups and private equity companies who is raising money hcr value fund lp funding details hcr value fund lp industry pooled investment fundcik number irs number address  westminster street th floor providence phone number  latest news hcr value fund lp raised  from  investors on  hcr value fund lp filings datefiling typeofferedsoldremainingmin investmentinvest countexemption  exlusions amended form dindefiniteindefiniteb c csec filingnew form db c csec filingamended form dindefiniteindefinite c csec filingnew form dindefiniteindefinitesec filing hcr value fund lp raised  in total directors and executives of hcr value fund lp key people in hcr value fund lp na hcr value fund gp llcna clearpath wealth management llcpatrick churchville similar companieshcrp overflow fund lpseries b hcr stafford fund lp hcr omers fund lp hcr hop fund lp last visited companies abattis bioceuticals corp china green agriculture inc fitist corp harvest power inc john hancock life insurance co usa separate account p  whoisraisingmoneycom daily updated news about investment into startups hedge funds and private equity companies healthcare royalty partners  team hc royalty partners about approach team portfolio news contact team team strategic advisory board we are former surgeons pharmaceutical executives bankers equity analysts lawyers and consultants we have decades of investment operational clinical structuring and capital markets experience our strategic advisory board consists of prominent healthcare veterans that enhance the depth and expertise of our team carlos m almodovar principalinvestor relations li s boynton associate gregory b brown md founder thomas k conner chief financial officer warren d cooper mb bs bsc mfpm chief medical officer todd c davis founder samuel d floyd ii associate clarke b futch founder paul j hadden managing director shin w kang phd vice president joshua d kurtz fund controller sean s mansoory associate anthony g rapsomanikis vice president andrew t reardon chief legal officer spencer h schneider ip counsel  chief compliance officer john a urquhart principal amy j vayalattu fund accountant conrad wang md principal christopher a white chief operating officer ting xie phd senior associate clickablefitted our strategic advisory board consists of world renowned healthcare experts with extensive expertise in global manufacturing clinical medicine commercialization of life science products and licensing frank m armstrong md louis p berneman michael g carter md marc d kozin robert s langer scd julie h mchugh natale s ricciardi clickablefitted spotlight gregory b brown md founder gregory b brown md is a cofounder and vice chairman of hcr and the chairman of the strategic advisory board educated as a transplantation immunologist and trained as a thoracic and vascular surgeon dr brown practiced thoracic and vascular surgery in a community setting where he also founded and led an hmo he brings particular expertise in the scientific technical clinical and medical evaluation of products as well as in healthcare systems and payor  reimbursement dynamics he has been involved in sourcing diligencing and closing more than  billion of royalty financings before cofounding hcr dr brown was a partner at paul capital partners where he comanaged that firms royalty investments as a member of the royalty management committee prior to beginning his principal investment career in  dr brown was cohead of investment banking and head of healthcare at adams harkness  hill now canaccord genuity and a ranked biotechnology research analyst at vector securities international dr brown holds a ba from yale an md from suny upstate medical center and an mba from harvard business school he currently serves on the board of monosol rx and is a board observer at vanderbilt sarl li s boynton associate li s boynton joined hcr as an associate in  previously she worked in equity research covering the large cap pharma and largesmid cap biotechnology sectors at guggenheim ms boynton holds a bs in molecular biology from yale university todd c davis founder todd c davis is a cofounder managing partner and chairman of the portfolio management committee at hcr he has particular expertise in the commercial operational and licensing aspects of the healthcare industry and is responsible for the management of hcrs existing portfolio of over  billion mr davis has been involved in over  billion in healthcare principal investments including sourcing conducting due diligence and closing more than  billion in royalty financings in addition mr davis has run hcrs business development activities coordinated the firms public relations activities and served on the investment committee previously mr davis was a partner at paul capital partners where he comanaged that firms royalty investments as a member of the royalty management committee he also served as a partner responsible for biopharmaceutical growth equity investments at apax partners prior to beginning his principal investment career in  mr davis held sales and marketing roles at abbott laboratories and worked in business development licensing and general management at elan pharmaceuticals mr davis holds a bs from the us naval academy and an mba from harvard business school he currently serves on the boards of suneva medical ligand pharmaceuticals acufocus and tearscience clarke b futch founder clarke b futch is a cofounder managing partner and chairman of the investment committee at hcr he has been raising and deploying capital in the healthcare royalty market for more than a dozen years since  he has led more than  royalty investments representing nearly  billion of invested capital over the course of his career mr futch has raised over  billion across five investment funds and executed more than  transactions including royalty equity debt and ma deals at hcr partners he also leads the firms fundraising activities before cofounding hcr mr futch served as a partner at paul capital partners where he comanaged the firms royalty investments as a member of the royalty management committee he previously served as a founder of the healthcare group at thomas weisel partners and as a vice president at raymond james mr futch was previously named one of the future leaders in biotech finance by bioworld one of the industrys leading publications he holds a ba magna cum laude from vanderbilt university and a jd from the university of virginia school of law mr futch also serves on the board of suneva medical paul j hadden managing director paul j hadden is a managing director and member of the investment committee at hcr he joined the firm in  and is focused primarily on hcrs activities in the united kingdom and europe including deal sourcing and structuring mr hadden has previously led the firms efforts with universities and inventors as well as its global business development activities mr hadden has over a decade of experience investing in and advising biotechnology and pharmaceutical companies and to date has been involved in sourcing conducting due diligence andor closing over  million in royalty transactions prior to hcr mr hadden served as a principal at the frankel group llc a boutique management consulting firm serving the life sciences industry where he advised leading pharmaceutical biotechnology and generic clients mr hadden started his career at new yorkpresbyterian hospital as a senior financial analyst providing financial planning support to the program development and clinical services division mr hadden holds a ba from yale college and an mph from the yale school of public health conrad wang md principal conrad wang md joined hcr as a principal in  trained as an orthopedic surgeon dr wang has over a decade of experience investing and structuring acquisitions in healthcare dr wang most recently was senior director corporate development at medtronic plc where he led crossfunctional deal teams in evaluating and executing acquisitions strategic alliances joint ventures and minority investments prior to medtronic dr wang was a principal investor at three arch partners a healthcare venture capital firm where he sourced invested in and was a board member for medical device healthcare services and therapeutics companies dr wang holds a bs from massachusetts institute of technology mit an md from the harvardmit division of health sciences and technology at harvard medical school and an mba from harvard business school where he was named a baker scholar he completed his postgraduate training in the harvard combined orthopedic residency program he currently serves as a board observer for acufocus and tearscience cici zheng associate cici zheng is an associate of hcr prior to joining hc royalty she was an analyst in the healthcare investment banking division at ubs investment bank where she focused on mergers and acquisitions as well as debt and equity financings across the healthcare industry ms zheng holds a ba from the university of pennsylvania emilie c mckenna associate emilie mckenna is an associate of hcr prior to joining hcr she was an analyst in the healthcare investment banking group at cowen and company where she focused on mergers and acquisitions as well as debt and equity financings ms mckenna holds a ba from bowdoin college sean s mansoory associate sean s mansoory joined hcr as an associate in  previously he worked in the healthcare investment banking groups at bmo capital markets and janney capital markets prior to janney he worked as a market research analyst at boston biomedical consultants now quintilesims a boutique consulting firm primarily focused on the in vitro diagnostics ivd sector sean holds a bs in biochemistry and premedicine from trinity college ct shin w kang phd vice president shin w kang phd joined hcr as a vice president in  dr kang focuses on hcrs research efforts as well as business development related to us based universities and inventors he most recently served as a vice president of equity research at wells fargo securities covering the biotechnology sector prior to wells fargo dr kang managed technology intellectual property and business development at the mount sinai school of medicine he holds a phd in biological chemistryimmunology from the university of california los angeles an mba from columbia business school and a bs from the university of california davis dr kang also conducted research at genentech as a postdoctoral fellow john a urquhart principal john a urquhart is a principal at hcr mr urquhart joined hcr in  and since then he has served various roles of increasing responsibility he has over a decade of healthcare investing experience in the royalty and structured finance market mr urquhart is based in boston and is responsible for the firms business development efforts in the greater boston region prior to hcr mr urquhart was an investment banking analyst at cowen and company where he focused on mergers and acquisitions as well as debt and equity financings mr urquhart holds a ba from brown university and a mba from the wharton school of the university of pennsylvania anthony g rapsomanikis director of west coast business development anthony g rapsomanikis is vice president and director of west coast business development at hcr prior to joining the firm in  as an associate he worked as an analyst in the healthcare investment banking group at stifel nicolaus weisel and its predecessor firm thomas weisel partners where he was focused on mergers and acquisitions debt and equity financings prior to stifel mr rapsomanikis was an analyst at silverwood partners where he advised middle market companies on private capital raises and ma transactions mr rapsomanikis holds a bba cum laude from the university of massachusetts amherst pei zhou cfa associate pei zhou cfa joined hcr as an associate in  previously he worked as an investment banking analyst at mts health partners a boutique healthcare merchant bank prior to mts he worked in corporate finance at comcastnbcuniversal pei holds a ba in economics from the university of pennsylvania ting xie phd senior associate ting xie phd joined hcr as an associate in  previously he was a member of ab bernsteins ii ranked equity research team covering biotech and specialty pharma sectors dr xie holds a phd from harvard university where he focused on cuttingedge small molecule drug development and related clinical studies at harvard medical school and danafarber cancer institute prior to that he received his bsc in chemistry and biology from tsinghua university thomas k conner chief financial officer thomas k conner is the chief financial officer and a managing director at hcr prior to joining hcr mr conner was the coo of investment banking at cowen  company mr conner spent more than twenty years with cowen  company and was its chief financial officer until its merger with ramius prior to joining cowen mr conner worked for tlp leasing programs where he managed the accounting operations of  public and private limited partnerships previously mr conner worked for atlantic capital corporation he began his career at deloitte haskins  sells in  mr conner holds a bba from the university of massachusetts amherst and is a certified public accountant licensed in the state of new york andrew t reardon chief legal officer andrew t reardon is the chief legal officer at hcr prior to joining hcr mr reardon was a senior associate at willkie farr  gallagher mr reardons experience includes advising private equity funds hedge funds lenders and operating companies on matters including fund formations financings equity issuances mergers and acquisitions leveraged buyouts royalty transactions restructurings and corporate governance mr reardon received a jd with high distinction from the university of iowa college of law where he was the recipient of the alan i widiss faculty scholar award and a ba with honors from the state university of new york college at old westbury mr reardon is a former officer with the united states army national guard spencer h schneider ip counsel  chief compliance officer spencer h schneider is the chief compliance officer and intellectual property counsel at hcr mr schneider helped establish hcrs compliance program handled all aspects of the firms registration as an investment advisor with the sec and manages all compliance functions  he is a registered patent attorney with extensive experience in conducting intellectual property due diligence for corporate transactions prior to joining hcr mr schneider was a principal at speyside capital advisors a boutique advisory firm helping to facilitate commercialization of university inventions previously mr schneider was an associate in the intellectual property groups of dewey  leboeuf ropes  gray and cooper  dunham he has conducted patent due diligence for multiple types of transactions including public offerings venture capital financings mergers and acquisitions leveraged buyouts and royalty transactions mr schneider holds a ba in biology from columbia college a ms in biochemistry and molecular biology from new york medical college and a jd from cardozo school of law frank m armstrong md frank m armstrong md is a member of hcrs strategic advisory board over the course of his tenured career dr armstrong has served as chief executive officer at a number of healthcare and biopharmaceutical companies including fulcrum pharma plc curagen corporation bioaccelerate holdings inc provensis ltd and phoqus pharmaceuticals plc dr armstrong has also worked in big pharma as head of worldwide product development at bayer ag a senior vice president at zeneca pharmaceuticals now astrazeneca plc and a senior vice president at merck serono dr armstrong holds an mbchb from the university of edinburgh and became a member of the royal college of physicians in  he was elected a fellow of the royal college of physicians edinburgh in  and was elected a fellow of the faculty of pharmaceutical physicians in  michael g carter md michael g carter md is a member of hcrs strategic advisory board and investment committee dr carter is a venture partner at sv life sciences advisers llp and serves as a nonexecutive director of micromet inc fulcrum pharma plc santarus inc and gtx inc previously dr carter was a member of the strategic advisory board for the paul royalty funds from  to  dr carter held numerous positions with zeneca pharmaceuticals now astrazeneca plc including international marketing director international medical director and serving on that companys board dr carter also held numerous positions with roche products ltd from  to  including director of the pharmaceutical division head of medical development and medical affairs and an adverse reactions physician for nearly a decade he served on the uk governments medicines commission and prior to entering the pharmaceutical industry was a practicing physician dr carter holds a diploma in pharmaceutical medicine an mbchb from sheffield university medical school a bpharm from london universitys school of pharmacy and is a member of the pharmaceutical society he was elected a fellow of the royal pharmaceutical society a fellow of faculty of pharmaceutical medicine of the royal college of physicians and a fellow of the royal college of physicians edinburgh nicholas l teti jr nicholas l teti jr is a member of hcrs strategic advisory board he is chairman of the board and ceo of suneva medical prior to suneva medical mr teti was chairman of the board of isolagen inc and until january  was also the companys chief executive officer previously mr teti served as chairman president and chief executive officer of the inamed corporation from  through the allergan acquisition prior to inamed mr teti spent twentyfive years at dupont and dupont merck where he held a number of senior management positions including president and ceo of dupont pharmaceuticals he currently serves on the board of enteromedics mr teti holds a ba and an mba from st josephs university louis p berneman lead advisor nonprofit institutions louis p berneman serves as the lead advisor nonprofit institutions for hcr mr berneman is a past president of the association of university technology managers autm a global network of more than  universities and other nonprofit research institutions focused on licensing technology created through academic and nonprofit research he is also a former vice president and trustee of the licensing executives society les a professional licensing and technology transfer society comprised of over  members mr berneman served on the strategic advisory board for the paul royalty funds for nine years and was managing director of the center for technology transfer at the university of pennsylvania currently mr berneman heads texelerate llc a technology transfer consultancy focusing on assisting institutions investors entrepreneurs and companies with licensing transactions royalty monetizations and creating financing for startups he is also a founding partner of osage university partners mr berneman holds a ba from the pennsylvania state university a teaching credential from university of california at santa barbara and an ma mt and ed d from teachers college columbia university he is also a certified licensing professional joshua d kurtz fund controller joshua d kurtz is a fund controller at hcrp prior to joining hcr mr kurtz was a fund accounting manager at chilton investment company where he was a team leader within the group and managed all aspects of the fund accounting functions before joining chilton mr kurtz worked at cowen investment management formerly ramius where he served as a vice president in the accounting group responsible for accounting and financial reporting for multiple investment funds prior to ramius mr kurtz was a senior accountant in the audit assurance services investment management division of deloitte and touche where he specialized in the audits of private equity and hedge funds mr kurtz holds a bba from baruch college and is a certified public accountant licensed in the state of new york carlos m almodovar principal  investor relations carlos m almodovar is a principal in the investor relations group at hcr prior to joining hcr mr almodovar was director business development at strategic value partners an alternative investment firm focused on distressed debt prior to joining strategic value partners mr almodovar served as an associate director for ubs investment bank where he focused on raising capital for external private equity managers before ubs investment bank mr almodovar served as an analyst in real estate for lehman brothers mr almodovar holds a bs from cornell university robert s langer scd robert s langer scd is a member of hcrs strategic advisory board he is a david h koch institute professor and founder of the langer lab at the massachusetts institute of technology dr langer previously served as a member of the united states food and drug administrations science board the fdas highest advisory board from    and as its chairman from  he has helped start  companies and more than  pharmaceutical chemical biotechnology and medical device companies have licensed or sublicensed langer lab patents over the course of his tenured career dr langer has received over  major awards including the  wolf prize in chemistry which is considered the isreali nobel prize the  united states national medal of science the  united states national medal of technology and innovation and the charles stark draper prize the equivalent of the nobel prize for engineers he has also been elected to the institute of medicine of the national academy of sciences the national academy of engineering and the national academy of sciences dr langer has received  honorary doctorates including honorary degrees from both harvard and yale he received his bachelors degree from cornell university and his scd from massachusetts institute of technology both in chemical engineering julie h mchugh julie h mchugh is a member of hcrs strategic advisory board ms mchugh most recently served as chief operating officer for endo health solutions inc from march  through may  where she was responsible for the specialty pharmaceutical and generic drug businesses prior to joining endo ms mchugh was the chief executive officer of nora therapeutics inc a venture capital backed biotech startup company focused on developing novel therapies for the treatment of infertility disorders before that she served as company group chairman for johnson  johnsons jj worldwide virology business unit and previously she was president of centocor inc a jj subsidiary while at jj ms mchugh oversaw the development and launches of several products including remicade® infliximab prezista® darunavir and intelence® etravirine and she was responsible for oversight of a research and development portfolio including compounds for hiv hepatitis c and tuberculosis prior to joining centocor ms mchugh led the marketing communications for gastrointestinal drug prilosec® omeprazole at astramerck inc she currently serves on the board of visitors for the smeal college of business of the pennsylvania state university as well as on the board of directors of ironwood pharmaceuticals inc aerie pharmaceuticals inc epirus biopharmaceuticals inc and trevena inc all publicly held companies and the new xellia group a privately held company she previously served on the board of directors for viropharma inc the biotechnology industry organization bio the pennsylvania biotechnology association and the new england healthcare institute nehi ms mchugh received her mba from st josephs university and her bs from pennsylvania state university marc d kozin marc d kozin is a member of hcrs strategic advisory board he is a senior advisor and former president of lek consulting a global management consulting firm that helps clients solve their most critical business problems mr kozin has  years of experience in strategy consulting and ma management both domestically and internationally he also has deep industry expertise advising biopharmaceutical life sciences and medtech companies during his tenure at lek mr kozin advised senior executives in life sciences and other industries to help them identify new growth opportunities build value pursue highlyprofitable mergers and acquisitions and support sustained growth he helped open the firms boston office in  and oversaw the growth of the firms us operations including the companys acquisition of shareholder value consulting firm alcar in  in  consulting magazine named mr kozin one of the  most influential consultants in recognition of his leadership and results for clients he holds a ba magna cum laude in economics from duke university and an mba with distinction from the wharton school at the university of pennsylvania mr kozin currently sits on the boards of endocyte inc dyax corporation helomics™ corporation medical simulation corporation ufp technologies and crunchtime information systems neil j campbell neil j campbell joined hcr as an advisor in  he currently serves as president  ceo of helomics™ corporation chairman of mosaigen® corporation and as a senior research fellow at the university of liverpool over the course of his career mr campbell has successfully developed andor introduced more than  products and services in the areas of pharmaceuticals medical devices clinical  industrial diagnostics consumer healthcare products medical software research products bioinformatics nanotechnology highperformance computing and internetofthings he has held clevel positions at child health research institute supernova diagnostics inc endeavour capital entremed pharmaceuticals nasdaq enmd and celera genomics nasdaqcra mr campbell has also served in general and executive management positions at life technologies inc nasdaq life igen inc acquired by roche nasdaqigen and abbott laboratories nyse abt mr campbell serves on several industry government nonprofit and company boards and is an active author on a wide variety of subjects relating to the research development and commercialization of science and technology he is pursuing a doctorate from the university of liverpool and holds an mba and ma from webster university and a bsba from norwich university warren d cooper mb bs bsc mfpm warren d cooper mb bs bsc mfpm is the chief medical officer and a managing director at hcr partners dr cooper previously served as an industry advisor to hcr partners he is a uktrained physician with over  years of experience in the global pharmaceutical industry dr cooper was the founding ceo of prism pharmaceuticals a venturebacked specialty pharmaceutical company that he led from inception to the sale of the company to baxter international in may  with a background in cardiology and cardiac surgery he spent  years with merck initially as a uk clinical research physician then as head of european and subsequently worldwide clinical research operations for merck research laboratories across all therapeutic areas moving to astramerck now astrazeneca plc he led that companys cardiovascular business division a role with full business lifecycle leadership from inlicensing through development to pl responsibility for sales and marketing dr cooper currently serves as the lead director on the board of zynerba pharmaceuticals and is a member of the faculty of pharmaceutical medicine of the royal colleges of physicians of the united kingdom and of the international society of hypertension natale s ricciardi natale s ricciardi is a member of hcrs strategic advisory board he spent his entire year biopharmaceutical career at pfizer inc prior to his retirement in  mr ricciardi served as president pfizer global manufacturing senior vice president pfizer inc and as a member of the pfizer executive leadership team in addition to his corporate leadership role mr ricciardi was directly responsible for all of pfizers internal and external supply organization – a global enterprise with as many as  employees and more than  manufacturing facilities supplying small and large molecule pharmaceuticals vaccines consumer nutrition and animal health products by working with research from product codevelopment regulatory approvals manufacturing and launch his first decade at pfizer was spent performing technical and supervisory roles in the new york area mr ricciardi then relocated to puerto rico where he led pfizers growing manufacturing operations and ultimately included sales and marketing in the caribbean he returned to the mainland in  as vice president of manufacturing for pfizers animal health group in  he was given responsibility for pfizers us manufacturing operations and assumed global responsibilities in  mr ricciardi holds a bs in chemical engineering from the city college of new york and an mba in finance and international business from fordham university  he currently serves on the board of directors of dynavax technologies amy j vayalattu fund accountant amy j vayalattu joined hcr as a fund accountant in  she previously served as an assurance associate in the financial services group at mcgladrey llp in this role she was responsible for conducting risk analysis and audits for private equity funds fundoffunds and hedge funds she previously served in the federal tax department at ibm amy holds a ba in public accounting from pace university christopher a white chief operating officer christopher a white joined hcr as chief operating officer in  and became a member of the investment committee in  he has over twenty years of legal financial and operational experience he previously served as managing director and head of investment banking at janney montgomery scott llc where he was responsible for leading the strategic direction business development and corporate finance activities of the investment banking division within the capital markets group prior to joining janney in  mr white spent over a decade at cowen group inc where he held a number of senior management positions including chief administrative officer chief financial officer and chief operating officer he previously served in senior leadership positions at salomon smith barney and spent seven years as a securities and mergers and acquisitions lawyer mr white holds a ba from amherst college and a jd from the university of michigan law school samuel d floyd ii associate samuel d floyd ii joined hcr as an associate in  previously he worked in the financial sponsors group of the jp morgan private bank where he advised senior private equity professionals regarding their investing banking credit and estate planning needs mr floyd holds a bs magna cum laude from the sybil c mobley school of business at florida am university copyright   healthcare royalty partners  disclaimer follow us   swcshcr quote  swisscanto lu bond fund secured high yield  bloomberg markets error could not add to watchlist x  watchlist swisscanto lu bond fund secured high yield swcshcrlx chf   as of  am edt  fund type openend fund wk range     yr return  ytd return  before its here its on the bloomberg terminal learn more previous close  wk range     yr return  ytd return  fund type openend fund objective high yield bond asset class focus fixed income geographic focus global nav on   total assets m usd on   inception date  last dividend on   dividend indicated gross yield  fund managers roland hausheer  susanne kundert front load fee  back load fee  redemption fee  b fee  current mgmt fee  expense ratio  profile swisscanto lu bond fund secured hy is an openend fund incorporated in luxembourg the objective of the fund is to provide high current income generation and where appropriate capital appreciation the fund will invest in a portfolio of senior secured fixed and floating rate corporate debt instruments  focusing on north america and europe and exclude ccc rated securities address swisscanto fondsleitung agbahnhofstrasse  zuerich phone tel      website wwwswisscantoch ﻿ todd asset management llc buys  shares of emerson electric company nyseemr  chaffey breeze daily ratings  news for emerson electric company complete the form below to receive the latest headlines and analysts recommendationsfor emerson electric company with our free daily email newsletter follow chaffeybreeze recent posts bank of america corporation bac position held by united fire group inc imperial oil ltd imo stake decreased by ubs group ag genesee  wyoming inc nysegwr position cut by bank of america corp de aflac incorporated nyseafl shares bought by nomura asset management co ltd canadian apartment properties reit announces monthly dividend of  car student transportation inc stb to issue monthly dividend of  nuveen asset management llc sells  shares of twentyfirst century fox inc fox metropolitan life insurance co ny holds position in capitol federal financial inc cffn costco wholesale corporation cost is rkl wealth management llc’s th largest position todd asset management llc buys  shares of emerson electric company nyseemr invesco dynamic credit opportunities fd nysevta given daily news sentiment rating of  one gas ogs earns daily news impact score of  eaton corporation plc etn receiving positive press coverage report shows norsat international nysensat receives daily media impact rating of  broadsoft nasdaqbsft receives media impact score of   million in sales expected for hanmi financial corporation hafc this quarter financial analysis cheniere energy partners lp holdings nysecqh vs dominion midstream partners dm public employees retirement system of ohio maintains position in paychex inc nasdaqpayx nuveen asset management llc lowers stake in enable midstream partners lp nyseenbl stillwater mining company nyseswc position maintained by teachers retirement system of the state of kentucky todd asset management llc buys  shares of emerson electric company nyseemr posted by charlotte bryant on jul th   no comments todd asset management llc increased its position in shares of emerson electric company nyseemr by  during the first quarter holdings channel reports the fund owned  shares of the industrial products company’s stock after buying an additional  shares during the period todd asset management llc’s holdings in emerson electric were worth  at the end of the most recent quarter other large investors also recently bought and sold shares of the company thrivent financial for lutherans raised its position in shares of emerson electric by  in the fourth quarter thrivent financial for lutherans now owns  shares of the industrial products company’s stock worth  after buying an additional  shares in the last quarter gsb wealth management llc acquired a new position in shares of emerson electric during the fourth quarter worth  hanlon investment management inc acquired a new position in shares of emerson electric during the fourth quarter worth  miles capital inc raised its position in shares of emerson electric by  in the fourth quarter miles capital inc now owns  shares of the industrial products company’s stock worth  after buying an additional  shares in the last quarter finally ae wealth management llc acquired a new position in shares of emerson electric during the fourth quarter worth   of the stock is currently owned by hedge funds and other institutional investors get emerson electric company alerts shares of emerson electric company emr opened at  on wednesday emerson electric company has a one year low of  and a one year high of  the firm has a market capitalization of  billion a pe ratio of  and a beta of  the company has a day moving average price of  and a  day moving average price of  emerson electric nyseemr last released its quarterly earnings data on tuesday may nd the industrial products company reported  earnings per share eps for the quarter meeting the consensus estimate of  emerson electric had a net margin of  and a return on equity of  the business had revenue of  billion during the quarter compared to analyst estimates of  billion during the same quarter in the previous year the business earned  eps emerson electric’s quarterly revenue was down  compared to the same quarter last year analysts expect that emerson electric company will post  earnings per share for the current fiscal year copyright violation warning “todd asset management llc buys  shares of emerson electric company nyseemr” was first reported by chaffey breeze and is owned by of chaffey breeze if you are accessing this story on another site it was illegally copied and reposted in violation of united states  international copyright and trademark laws the original version of this story can be accessed at httpswwwchaffeybreezecomtoddassetmanagementllcbuyssharesofemersonelectriccompanynyseemrhtml a number of research analysts have weighed in on the company stifel nicolaus reissued a “buy” rating and set a  price target on shares of emerson electric in a research note on wednesday july th morgan stanley reissued an “overweight” rating on shares of emerson electric in a research note on tuesday july th jmp securities assumed coverage on emerson electric in a research note on monday june th they set an “outperform” rating and a  price target on the stock bidaskclub raised emerson electric from a “sell” rating to a “hold” rating in a research note on friday june th finally royal bank of canada reissued a “hold” rating and set a  price target on shares of emerson electric in a research note on tuesday june th three research analysts have rated the stock with a sell rating fifteen have given a hold rating and three have issued a buy rating to the company the company has a consensus rating of “hold” and a consensus price target of  emerson electric company profile emerson electric co is a diversified global manufacturing company which provides solutions to customers by bringing technology and engineering together in the industrial commercial and consumer markets around the world the company operates through four segments based on the nature of the products and services rendered process management industrial automation climate technologies and commercial  residential solutions want to see what other hedge funds are holding emr visit holdingschannelcom to get the latest f filings and insider trades for emerson electric company nyseemr receive news  ratings for emerson electric company daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for emerson electric company and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website nys home program home your browser does not support iframes skip to main content navigation menu homes and community renewal rental housing for renters for rental owners  managers office of rent administration rental housing forms tenant protection unit home ownership for homebuyers  sonyma for homebuyers  alternatives for homeowners for homeownership professionals housing partners funding rfps and awards multifamily projects developers notforprofit organizations  municipalities state managed programs hcr sign specifications doing business with us hcr procurement opportunities procurement and contract information minority and womenowned business enterprises information about us home page  programs  new york state home program home new york state home program home about the nys home program home the new york state home program is administered by the new york state housing trust fund corporation htfc the program uses federal home investment partnership program funds to expand the supply of decent safe and affordable housing within the state the home program funds a variety of activities through partnerships with counties towns cities villages private developers and communitybased nonprofit housing organizations the program provides funds to acquire rehabilitate or construct housing or to provide assistance to lowincome homebuyers and renters funds must be distributed in accordance with needs and priorities identified in the states consolidated plan federal home program regulations  cfr part  set forth requirements for formula allocations eligible activities matching funds qualifications as affordable housing and compliance with other federal requirements the regulations also establish special requirements for community housing development organizations chdos project selection shall take into consideration the recommendation of the relevant regional economic development council or the commissioners determination that the proposed project aligns with the regional strategic priorities of the respective region eligible applicants any private forprofit or notforprofit entity that can demonstrate the capacity to develop and operate a qualifying project is eligible to apply for home project funding units of general local government that have not been designated by hud as participating jurisdictions and notforprofit corporations that meet certain administrative tests may also apply as local program administrators jurisdictions which receive home program funding directly from the federal government may not apply for new york state home program funds eligible areas all areas of the state are eligible subject to the funding limitations described below income eligibility home program funds may only be used to assist households with incomes at or below  percent of area median income rental projects must primarily serve households with incomes at or below  percent of area median income assisted rental units must remain affordable for a period of between five and  years depending on the initial amount of subsidy provided for the project funding limitations home program funds may be used to pay for acquisition rehabilitation construction and certain related soft costs funds may also be used for relocation costs tenantbased rental assistance down payment and closing costs and some administrative and planning costs subject to limitations set forth in the federal regulations funds may only be used for residential housing there are restrictions on the use of home funds for properties assisted by certain other federal programs fifteen percent of each allocation of home program funds is reserved for qualified community housing development organizations chdo in accordance with federal law of the remaining funds a minimum of  percent is reserved for projects that are not located in communities that have been designated by hud as participating jurisdictions program information nys home local program budget policy  awardee orientation webinar  pdf version owner occupied rehabilitation workshop – pdf version homebuyer workshop – pdf version nyshcr – home mandatory homebuyer presentation video – april  nys home local program homebuyer recaptureresale provisions  home rule update presentation with notes by monte franke current funding opportunities  new capital programs manual  section  home  cdbg residential antidisplacement  relocation assistance plan  home relocation and cdbg appeal process environmental review requirements and materials for local program administrators forms home local program administrators home local program administrator projects environmental review home program monitoring guide for state recipients and subrecipients home program rehabilitation standards pdf version of home program rehabilitation standards funding awards home information from hud home investment partnerships program   homes and community renewal rental housing opportunities to apply for affordable rental units nyhousingsearchgov section  housing choice voucher tenant protection unit office of rent administration rent stabilizationcontrol forms  information by topic home ownership sonyma products for firsttime homebuyers information for sonyma participating lenders foreclosure prevention mitchelllama housing current interest rates housing partners funding opportunities funding awards capital programs municipalities doing business with us forms and applications hcr procurement opportunities procurement and contract information economic opportunity corner about us about the agency contact us freedom of information law foil our agencies offices job opportunities  internships press room public meetings hcr weatherrelated closing information connect with us facebook flickr twitter youtube your browser does not support iframes